GHC Research Development Corporation
Records under this name other than patents GHC Research Development Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to GHC Research Development Corporation
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,777,004 | Polypeptides comprising Fas activation and NKG2D-ligand domains Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 7,550,426 | Acetylated therapeutic procytotoxins Formerly held Term ended Term ended May 16, 2026 · From the USPTO record | Term ended | Term ended May 16, 2026 | From the USPTO record |
| US 7,339,027 | Human Prolactin Antagonist-Angiogensis Inhibitor Fusion Proteins Formerly held Term ended Term ended Feb 1, 2025 · High confidence | Term ended | Term ended Feb 1, 2025 | High confidence |
| US 7,582,726 | VEGF receptor antagonists Formerly held Term ended Term ended Jan 17, 2025 · From the USPTO record | Term ended | Term ended Jan 17, 2025 | From the USPTO record |
| US 7,456,146 | Lytic peptide prodrugs Formerly held Term ended Term ended Mar 11, 2024 · From the USPTO record | Term ended | Term ended Mar 11, 2024 | From the USPTO record |
| US 7,201,905 | Bi-functional cancer treatment agents Formerly held Term ended Term ended Sep 14, 2023 · From the USPTO record | Term ended | Term ended Sep 14, 2023 | From the USPTO record |
| US 7,425,535 | Therapeutic pore-forming peptides Formerly held Term ended Term ended Aug 4, 2022 · From the USPTO record | Term ended | Term ended Aug 4, 2022 | From the USPTO record |
| US 8,754,031 | Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway Formerly held Lapsed on the fee record Ended Jun 17, 2022 · From the USPTO record | Lapsed on the fee record | Ended Jun 17, 2022 | From the USPTO record |
| US 6,875,612 | Monocyte-specific particulate delivery vehicle Formerly held Term ended Term ended May 5, 2022 · From the USPTO record | Term ended | Term ended May 5, 2022 | From the USPTO record |
| US 7,632,809 | Multimeric ligands with enhanced stability Formerly held Lapsed on the fee record Ended Dec 15, 2021 · From the USPTO record | Lapsed on the fee record | Ended Dec 15, 2021 | From the USPTO record |